Literature DB >> 21566764

New drugs approved in 2010.

Erin Sears1, Tegan Steimel.   

Abstract

Year:  2011        PMID： 21566764      PMCID： PMC3069525          DOI： 10.1080/08998280.2011.11928706

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  16 in total

Review 1.  Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.

Authors:  D A Wohl; G McComsey; P Tebas; T T Brown; M J Glesby; D Reeds; C Shikuma; K Mulligan; M Dube; D Wininger; J Huang; M Revuelta; J Currier; S Swindells; C Fichtenbaum; M Basar; M Tungsiripat; W Meyer; J Weihe; C Wanke
Journal:  Clin Infect Dis       Date:  2006-07-27       Impact factor: 9.079

2.  Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.

Authors:  John S Sundy; Nancy J Ganson; Susan J Kelly; Edna L Scarlett; Claudia D Rehrig; William Huang; Michael S Hershfield
Journal:  Arthritis Rheum       Date:  2007-03

Review 3.  Scientific understanding and clinical management of Dupuytren disease.

Authors:  Barbara Shih; Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

Review 4.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546

5.  Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.

Authors:  Perdita Taylor; Carol Worrell; Seth M Steinberg; Rohan Hazra; Shirley Jankelevich; Lauren V Wood; Sheryl Zwerski; Robert Yarchoan; Steven Zeichner
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

6.  Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.

Authors:  John S Sundy; Michael A Becker; Herbert S B Baraf; Andre Barkhuizen; Larry W Moreland; William Huang; Royce W Waltrip; Allan N Maroli; Zeb Horowitz
Journal:  Arthritis Rheum       Date:  2008-09

7.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Authors:  M Marre; J Shaw; M Brändle; W M W Bebakar; N A Kamaruddin; J Strand; M Zdravkovic; T D Le Thi; S Colagiuri
Journal:  Diabet Med       Date:  2009-03       Impact factor: 4.359

8.  Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Authors:  Bernard Zinman; John Gerich; John B Buse; Andrew Lewin; Sherwyn Schwartz; Philip Raskin; Paula M Hale; Milan Zdravkovic; Lawrence Blonde
Journal:  Diabetes Care       Date:  2009-03-16       Impact factor: 17.152

9.  Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy.

Authors:  Agnieszka B Dzwonek; Margaret S Lawson; Tim J Cole; Vas Novelli
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

10.  Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Authors:  Michael Nauck; Anders Frid; Kjeld Hermansen; Nalini S Shah; Tsvetalina Tankova; Ismail H Mitha; Milan Zdravkovic; Maria Düring; David R Matthews
Journal:  Diabetes Care       Date:  2008-10-17       Impact factor: 17.152
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.